Trump Urges Congress to Update Law to Protect Access to Cannabidiol (CBD) Products

Trump calls on Congress to update federal law ensuring access to cannabidiol (CBD) products, urging clearer regulations for patients, farmers, and businesses.

Former President Donald Trump has urged Congress to update federal law to ensure access to cannabidiol (CBD) products, highlighting the need for clearer regulation as the market grows. Advocates say that regulatory uncertainty has left patients, farmers, and businesses in limbo, even after hemp legalization expanded opportunities for CBD production.

Cannabidiol (CBD), a non-intoxicating compound derived from hemp, has become popular for its potential therapeutic benefits. Consumers and medical patients increasingly seek CBD products for pain, anxiety, and other conditions, but inconsistent state laws and limited federal guidance complicate access. Trump’s call to action emphasizes the importance of a consistent national framework that balances public safety with consumer access.

Key policy goals include clarifying CBD’s legal status, streamlining FDA oversight, and protecting legitimate hemp farmers and small businesses. Many industry stakeholders want Congress to update the 2018 Farm Bill’s provisions and provide explicit pathways for CBD labeling, testing, and distribution. Clear federal rules could help prevent unsafe or mislabeled products and support economic growth in the hemp sector.

Supporters of reform point out that veterans and medical patients often face barriers when trying to obtain CBD. A cohesive federal law could improve patient access and remove legal ambiguities that deter doctors and retailers from recommending or stocking CBD products. At the same time, policymakers must address quality control, manufacturing standards, and accurate marketing claims to protect public health.

Regulatory clarity also matters for farmers. Hemp growers need predictable rules to invest in cultivation and processing. Updating the law could incentivize more domestic production, reduce reliance on imports, and strengthen rural economies. Businesses in the CBD supply chain—from processors to retail outlets—would benefit from a level playing field and reduced compliance uncertainty.

While changes to federal law would require bipartisan cooperation in Congress, proponents argue that a pragmatic, science-based approach could garner wide support. Any legislative update will likely involve coordination with the Food and Drug Administration (FDA) to establish safety standards and appropriate enforcement.

As conversations continue in Washington, consumers and industry observers will be watching for concrete proposals. Clearer CBD regulation could unlock economic opportunities, improve product safety, and ensure that patients who rely on cannabidiol products have reliable access nationwide.

Back